Csernansky JG - Search Results

1

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. Csernansky JG, et al. N Engl J Med. 2002 Jan 3;346(1):16-22. doi: 10.1056/NEJMoa002028. N Engl J Med. 2002. PMID: 11777998 Free article. Clinical Trial.

2

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.

Csernansky JG, Schuchart EK. Csernansky JG, et al. CNS Drugs. 2002;16(7):473-84. doi: 10.2165/00023210-200216070-00004. CNS Drugs. 2002. PMID: 12056922 Review.

3

Treatment of schizophrenia: preventing the progression of disease.

Csernansky JG. Csernansky JG. Psychiatr Clin North Am. 2003 Jun;26(2):367-79. doi: 10.1016/s0193-953x(02)00113-2. Psychiatr Clin North Am. 2003. PMID: 12778839 Review.

4

Correlates of cognitive deficits in first episode schizophrenia.

Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Heydebrand G, et al. Among authors: csernansky jg. Schizophr Res. 2004 May 1;68(1):1-9. doi: 10.1016/S0920-9964(03)00097-5. Schizophr Res. 2004. PMID: 15037334 Clinical Trial.

5

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network. Covell NH, et al. J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6. J Clin Psychiatry. 2012. PMID: 22480442 Free PMC article. Clinical Trial.

6

Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.

Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. Newcomer JW, et al. Among authors: csernansky jg. Psychiatry Res. 1992 Mar;41(3):191-202. doi: 10.1016/0165-1781(92)90001-j. Psychiatry Res. 1992. PMID: 1594706

7

The effects of kainic acid lesions on locomotor responses to haloperidol and clozapine.

Bardgett ME, Jackson JL, Taylor BM, Csernansky JG. Bardgett ME, et al. Among authors: csernansky jg. Psychopharmacology (Berl). 1998 Feb;135(3):270-8. doi: 10.1007/s002130050509. Psychopharmacology (Berl). 1998. PMID: 9498730

8

Limbic-cortical neuronal damage and the pathophysiology of schizophrenia.

Csernansky JG, Bardgett ME. Csernansky JG, et al. Schizophr Bull. 1998;24(2):231-48. doi: 10.1093/oxfordjournals.schbul.a033323. Schizophr Bull. 1998. PMID: 9613623 Review.

9

Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.

Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. Newcomer JW, et al. Among authors: csernansky jg. Psychopharmacol Bull. 1992;28(1):101-7. Psychopharmacol Bull. 1992. PMID: 1609034 Clinical Trial.

10

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Essock SM, et al. Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2. Am J Psychiatry. 2011. PMID: 21536693 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

299 results

Search Page